News Sentiment

SABS sentiment intelligence

SAB Biotherapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.82 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-2.6% over one week, +14.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction -2.6% Price reacting lower
Trend fit Trend inactive 14.7% over four weeks
Fair value -3.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 28
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 9
Market source 8
MarketBeat 6
TradingKey 3
MT Newswires 3
simplywall.st 3
Stock Titan 2
Insider Monkey 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 11
Analyst action 10
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
MarketBeat Direct company coverage

SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jul 2026

This article provides an updated analysis of SAB Biotherapeutics (SABS) short interest and short float as of July 2026. As of June 30, 2026, the short interest was 3.77 million shares, representing 5.33% of the public float, and marked a 31.17% increase since the prior report. Th

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 22:46
Source
MarketBeat
TradingView Direct company coverage

Breakthrough T1D funds PRISE-hATG to study SAB-142 in Stage 3 type 1 diabetes

Breakthrough T1D has awarded a grant to support the PRISE-hATG study, which will evaluate SAB-142 for preserving beta cell function in patients with Stage 3 Type 1 Diabetes (T1D). SAB Biotherapeutics will co-fund this trial, designed to assess SAB-142's ability to preserve endoge

Tone
Positive 75/100
Event
Market update
Published
07 Jul 2026 12:13
Source
TradingView
Stock Titan Direct company coverage

Grant backs SAB Biotherapeutics (NASDAQ: SABS) PRISE-hATG Stage 3 T1D trial

SAB Biotherapeutics has received a grant from Breakthrough T1D to support the PRISE-hATG clinical study of its lead candidate, SAB-142, for Stage 3 Type 1 Diabetes (T1D). This trial will evaluate SAB-142 in patients diagnosed between 100 days and two years, complementing SAB BIO'

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 12:13
Source
Stock Titan
Insider Monkey Direct company coverage

5 Overlooked Penny Stocks to Buy Right Now

This article highlights SAB Biotherapeutics, Inc. (NASDAQ: SABS) as an overlooked penny stock with significant upside potential. Analysts from Barclays and H.C. Wainwright have issued bullish ratings, citing a large market opportunity for its lead diabetes program, SAB-142, and r

Tone
Positive 92/100
Event
Market update
Published
04 Jul 2026 23:10
Source
Insider Monkey
TradingView Direct company coverage

SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap Financial Disclosures & SEC Filings

This page provides access to SAB Biotherapeutics, Inc. (SABSW) financial disclosures and SEC filings, including corporate presentations, earnings reports, and quarterly reports from 2023 to 2026. The documents highlight the company's progress with SAB-142, a disease-modifying the

Tone
Positive 70/100
Event
Earnings
Published
03 Jul 2026 19:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS

This article displays the "Price to sales forward" metric for SAB Biotherapeutics, Inc. (NASDAQ: SABS) on the TradingView platform. It shows the company's stock information, along with various navigation and product links typical of a financial charting website, but no specific f

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 07:09
Source
TradingView
Market source Direct company coverage

Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)

Barclays initiated coverage on SAB Biotherapeutics Inc. (SABS) with an Overweight rating and a $13 price target, projecting over 235% upside. Analyst Eliana Merle highlights SAB-142's potential as a disease-altering treatment for type 1 diabetes and believes the anticipated Phase

Tone
Positive 76/100
Event
Analyst action
Published
30 Jun 2026 16:40
Source
Market source
www.marketscreener.com Direct company coverage

SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell Microcap Index

SAB Biotherapeutics, Inc. (NasdaqCM: SABS) has been added to the Russell Microcap Index. The company is a clinical-stage biopharmaceutical firm focusing on human polyclonal immunotherapeutic antibodies for immunology disorders, with its lead product candidate, SAB-142, targeting

Tone
Positive 76/100
Event
Market update
Published
29 Jun 2026 06:11
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Value Benchmark

SAB Biotherapeutics, Inc. (NasdaqCM: SABS) has been added to the Russell 3000E Value Benchmark. The company is a clinical-stage biopharmaceutical company focusing on developing human polyclonal immunotherapeutic antibodies for immunology disorders, particularly Type 1 Diabetes. T

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 05:40
Source
www.marketscreener.com
TradingView Direct company coverage

Price to book forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW

The article provides information regarding the "Price to book forward" for SAB Biotherapeutics, Inc. (NASDAQ: SABSW) as listed on TradingView. It appears to be a financial data page showing a specific metric for the company, indicating key financial details for investors.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 17:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW

The article focuses on the "Price to sales forward" metric for SAB Biotherapeutics, Inc. (NASDAQ: SABSW). It appears to be a financial data page from TradingView, providing an overview of the company's financial data. The content is sparse, indicating that specific financial figu

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 10:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS

This article provides the enterprise value to EBITDA forward for SAB Biotherapeutics, Inc. (NASDAQ: SABS). It is presented on the TradingView platform, which offers financial data and tools for market analysis. The content indicates the data was "Made by humans" and is available

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 04:40
Source
TradingView
Investing.com Australia Direct company coverage

Form 4 SAB Biotherapeutics Inc For: 26 June By Investing.com

This article announces the filing of a Form 4 for SAB Biotherapeutics Inc on June 26, as reported by Investing.com. It is a brief corporate news item confirming a regulatory filing for the company. The article also provides a snapshot of various market data including indices, com

Tone
Neutral 50/100
Event
Regulatory and legal
Published
27 Jun 2026 01:40
Source
Investing.com Australia
Stock Titan Direct company coverage

[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity

SAB Biotherapeutics, Inc.'s Chief Medical Officer, Alexandra Kropotova, reported a Form 4 detailing a tax-withholding disposition of 988 common stock shares related to restricted stock unit vesting. After this transaction, she holds 42,308 shares, which includes 5,150 unvested RS

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:40
Source
Stock Titan
TradingView Direct company coverage

SABS Forecast — Price Target — Prediction for 2027

This article provides a forecast for SAB Biotherapeutics, Inc. (SABS) stock, including its price target, analyst ratings, and financial data. According to 12 analysts, the stock has a 1-year price forecast, with a current price of $3.80 and a maximum estimate of $16.00 and minimu

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 15:40
Source
TradingView
TradingView Direct company coverage

SAB Biotherapeutics, Inc. Actuals & Estimates (NASDAQ:SABS)

This article provides an overview of SAB Biotherapeutics, Inc. (NASDAQ: SABS) financials, stock performance, and analyst forecasts. As of the article's date, SABS stock is trading at $3.80 USD, having decreased by 1.81% in the past 24 hours but showing a 103.21% increase over the

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 15:40
Source
TradingView
Moomoo Direct company coverage

Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target

Barclays has initiated coverage on SAB Biotherapeutics with an Overweight rating and set a price target of $13. This indicates a positive outlook from the investment bank regarding the company's stock performance.

Tone
Positive 71/100
Event
Analyst action
Published
24 Jun 2026 17:11
Source
Moomoo
Investing.com Nigeria Direct company coverage

Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 By Investing.com

Barclays has initiated coverage on SAB Biotherapeutics Inc. (NASDAQ: SABS) with an Overweight rating and a $13 price target, citing the significant potential of its lead candidate, SAB-142, for type 1 diabetes prevention. The firm believes SAB-142 could address a market exceeding

Tone
Positive 74/100
Event
Analyst action
Published
24 Jun 2026 15:09
Source
Investing.com Nigeria
Investing.com Direct company coverage

Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13

Barclays has initiated coverage on SAB Biotherapeutics Inc. (NASDAQ:SABS) with an Overweight rating and a $13.00 price target, citing the potential of its lead candidate SAB-142 for type 1 diabetes prevention, which they estimate could exceed $4 billion in opportunity. Despite th

Tone
Positive 74/100
Event
Analyst action
Published
24 Jun 2026 11:40
Source
Investing.com
TradingKey Direct company coverage

SAB Biotherapeutics Inc (SABS) Institutional Confidence

This article provides an "Institutional Confidence" score for SAB Biotherapeutics Inc (SABS) as part of TradingKey's stock analysis. As of June 23, 2026, the company's institutional confidence score is 7.00. The article details major institutional shareholders and their sharehold

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 02:11
Source
TradingKey
Quartr Direct company coverage

SAB Biotherapeutics (SABS) 44th Annual J.P. Morgan Healthcare Conference Summary

SAB Biotherapeutics presented an overview of its strategic vision and clinical focus for its lead drug, SAB-142, at the 44th Annual J.P. Morgan Healthcare Conference. The drug, a fully human anti-thymocyte immunoglobulin, is in a pivotal Phase II-B trial for type 1 diabetes and a

Tone
Positive 74/100
Event
Market update
Published
19 Jun 2026 12:40
Source
Quartr
TradingKey Direct company coverage

SAB Biotherapeutics Inc (SABS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article attempts to provide a revenue breakdown for SAB Biotherapeutics Inc (SABS) but states that the relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It primarily serves as a placeholder page o

Tone
Neutral 50/100
Event
Earnings
Published
19 Jun 2026 05:39
Source
TradingKey
TradingKey Direct company coverage

SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of SAB Biotherapeutics Inc (SABS), listing major shareholders like Vivo Capital, LLC and Commodore Capital LP, and categorizing shareholder types. It also provides a historical overview of institutional shareholding from 2023Q4 to 20

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 04:39
Source
TradingKey
Investing.com Direct company coverage

SAB Biotherapeutics shareholders elect directors and approve auditor at annual meeting

SAB Biotherapeutics shareholders elected four Class II directors—Dr. David Zaccardelli, Katie Ellias, David Link, and Andrew Moin—and ratified EisnerAmper LLP as their independent public accounting firm for the fiscal year ending December 31, 2026, at the company's 2026 Annual Me

Tone
Positive 66/100
Event
Market update
Published
19 Jun 2026 01:39
Source
Investing.com